What Has Been the Growth Trajectory for the Mantle Cell Lymphoma Therapeutics Market in Recent Years?
The mantle cell lymphoma therapeutics market has seen considerable growth due to a variety of factors.
•In recent times, there has been a considerable increase in the market size of mantle cell lymphoma therapeutics. The market is projected to expand from $2.42 billion in 2024 to $2.62 billion in 2025, marking a compound annual growth rate (CAGR) of 8.2%.
Factors contributing to this growth during the historical period include advancements in research, successful clinical trials, enhanced diagnostic instruments, widened access to treatment, and collaborative research efforts.
How Does the Forecast Look for the Mantle Cell Lymphoma Therapeutics Market?
The mantle cell lymphoma therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market for therapeutics related to mantle cell lymphoma is anticipated to witness significant growth in the upcoming years. By 2029, it's projected to reach "$3.56 billion with an 8.0% compound annual growth rate (CAGR).
The increase during the forecasting period can be associated with the progression in targeted therapies, advancements in immunotherapy, personalized medicine movement, broader global market, and a surge in incidence rates. Important trends predicted in this timeframe include enhanced immunotherapy, development of precision medicine and biomarkers, targeted treatments for distinct pathways, combination therapies, and the inclusion of artificial intelligence (AI).
What Are The Leading Drivers Of Growth In The Mantle Cell Lymphoma Therapeutics Market?
The mantle cell lymphoma therapeutics market is anticipated to grow, spurred by the increasing occurrence of mantle cell lymphoma. This cancer affects the lymphatic system and is one among the types of non-Hodgkin lymphoma (NHL). The therapeutics for mantle cell lymphoma play a crucial role in minimizing its prevalence by managing the illness and improving patient outcomes, prolonging life expectancy, and reducing the burden of the disease. For example, as per the National Library of Medicine, a biomedical library in the US run by the United States Federal Government, in December 2022, the yearly incidence of mantle cell lymphoma was one case per 200,000 individuals, accounting for 5% of all non-Hodgkins lymphomas. Hence, the surge in mantle cell lymphoma instances is facilitating the expansion of the mantle cell lymphoma therapeutics market.
How Are The Segments Defined Within The Global Mantle Cell Lymphoma Therapeutics Market?
The mantle cell lymphoma therapeutics market covered in this report is segmented –
1) By Type: Combination Therapy, Monotherapy
2) By Mechanism of Action: Bruton Tyrosine Kinase Inhibitors, Alkylating Agents, Deoxyribonucleic Acid Synthesis Inhibitors, Microtubule Inhibitors, Monoclonal Antibodies, Other Mechanisms
3) By Route of Administration: Oral, Parenteral
4) By Application: Hospital, Research Institute, Other Applications
Subsegments:
1) By Combination Therapy: Chemotherapy Combinations, Targeted Therapy Combinations, Immunotherapy Combinations
2) By Monotherapy: Single-Agent Chemotherapy, Targeted Therapy Monotherapy, Immunotherapy Monotherapy
Pre-Book The Mantle Cell Lymphoma Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Mantle Cell Lymphoma Therapeutics Market?
One significant trend that is gaining traction in the mantle cell lymphoma therapeutics market is the innovation of targeted therapy drugs. To uphold their market stand, prominent companies in the mantle cell lymphoma therapeutics realm are focusing on the creation of novel drugs for targeted therapy. For instance, in March 2023, AstraZeneca plc., a pharmaceutical firm headquartered in the UK, gained approval for its drug, Calquence (acalabrutinib), from the National Medical Products Administration (NMPA) for distribution in China, intended for adult patients diagnosed with mantle cell lymphoma (MCL). Calquence (acalabrutinib) is a detailed Bruton’s tyrosine kinase (BTK) inhibitor, designed to present a more tolerable and efficient treatment alternative to manage mantle cell lymphoma.
Who Are the Key Players in the Mantle Cell Lymphoma Therapeutics Market?
Major companies operating in the mantle cell lymphoma therapeutics market include:
• AstraZeneca plc
• Celgene Corporation
• Johnson & Johnson Consumer Inc.
• Takeda Pharmaceutical Company Limited
• Bayer Aktiengesellschaft
• Eli Lilly and Company
• Amgen Inc.
• GlaxoSmithKline plc
• Kite Pharma Inc.
• Gilead Sciences Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Merck & Co. Inc.
• Massive Bio Inc.
• Juno Therapeutics Inc.
• Nurix Therapeutics Inc.
• Janssen Biotech Inc.
• TG Therapeutics Inc.
• F. Hoffmann-La Roche AG
• Astex Pharmaceuticals Inc.
• Astellas Pharma Inc.
• BeiGene Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Exelixis Inc.
• Hutchison China MediTech Limited
• Incyte Corporation
• Ionis Pharmaceuticals Inc.
What Is The Most Dominant Region In The Mantle Cell Lymphoma Therapeutics Market?
North America was the largest region in the global mantle cell lymphoma therapeutics market in 2024. The regions covered in the mantle cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
